ArticleFrontiers in pediatrics2026
Non-thrombotic manifestations in pediatric patients with persistent antiphospholipid antibodies. A Mexican tertiary center case series.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Antiphospholipid antibodies (aPL) are a group of autoantibodies classically associated with antiphospholipid syndrome (APS), a disease strongly linked to thrombosis and pregnancy loss. However, non-thrombotic manifestations are increasingly reported, including neurological, hematological, renal, and cardiac involvement. Information is limited at this level. Understanding the role of these antibodies is fundamental to rheumatological practice, especially in the pediatric population where information on this topic is limited. Objective: To describe non-thrombotic characteristics in pediatric patients with positive antiphospholipid antibodies at a tertiary care hospital in Mexico. Material and methods: A retrospective, observational, descriptive study was conducted. This study documented non-thrombotic clinical manifestations in pediatric patients with persistently positive antiphospholipid antibodies. Our patients did not meet the diagnostic criteria for antiphospholipid syndrome. Patients with thrombosis were not included in this study. All patients were evaluated by the pediatric rheumatology team. Results: Eighteen patients were included. Hematological alterations were the most prevalent (72% of patients presented with characteristics, including thrombocytopenia, hemolytic anemia, or leukopenia), followed by neurological manifestations. The most frequent antibody was anti-beta-2-glycoprotein-1, and 22% of patients had a triple positive profile. Conclusion: The most frequent manifestation reported in our group of patients with positive antiphospholipid antibodies was thrombocytopenia and hematological manifestations in general. The principal antibody reported was the anti-beta-2-glycoprotein-1. We need more studies to get a better understanding about the relation between positive antiphospholipid antibodies and non-thrombotic features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.